Literature DB >> 28668861

Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes.

Akio Kaito1,2, Takahiro Kinoshita3, Masanori Tokunaga1, Hideki Sunagawa1, Masahiro Watanabe1, Shizuki Sugita1, Akiko Tonouchi1, Reo Sato1, Iku Abe1, Tetsuo Akimoto2,4.   

Abstract

BACKGROUND: The role of para-aortic lymph node (PALN) dissection for far-advanced gastric cancer is controversial in patients with clinical PALN positivity who have responded to chemotherapy.
MATERIALS AND METHODS: We retrospectively analyzed long-term outcomes of patients with pathologically-positive PALNs who underwent radical gastrectomy.
RESULTS: The 3- and 5-year overall survival (OS) rates of 65 pathologically PALN-positive patients who underwent PALN dissection (n=704) were 33.8% and 21.2%, respectively. Multivariable analysis revealed the following poor prognostic factors: nodal involvement around the celiac axis (hazard ratio (HR)=4.04, 95% confidence interval (CI)=1.55-9.63), tumor diameter of ≥120 mm (HR=3.37; 95% CI=1.18-9.63) and ≥3 PALNs involved (HR=2.24; 95% CI=1.21-4.15). Patients with none of these factors survived significantly longer than those with any of these factors (5-year OS=87.5% versus 9.3%, respectively; p<0.001).
CONCLUSION: Pathologically PALN-positive patients achieve long survival; however, the indications for PALN dissection should be carefully considered. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Stomach neoplasms; extended lymphadenectomy; locoregional neoplasm recurrence; para-aortic lymph node; prognosis

Mesh:

Year:  2017        PMID: 28668861     DOI: 10.21873/anticanres.11740

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis.

Authors:  Shu-Bei Wang; Wei-Xiang Qi; Jia-Yi Chen; Cheng Xu; Wei-Guo Cao; Rong Cai; Lu Cao; Gang Cai
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 2.  Current status of extended 'D2 plus' lymphadenectomy in advanced gastric cancer.

Authors:  Jing-Quan Li; Donglei He; Yue-Xiang Liang
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.